BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Oncolytics Biotech Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Oncolytics Biotech Inc.'s drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07280377-9106@assetmemo.bio
DTSTAMP:20261121T010125Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pelareorep: Phase 1/2 readout est. (NCT07280377)
DESCRIPTION:Pelareorep\, phase 1/2.\nStudy: A Study in Advanced or Metastat
 ic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareor
 ep and Atezolizumab\nEstimated primary completion: 30 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pelareorep#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07280377
URL:https://assetmemo.bio/drug/pelareorep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446322-9106@assetmemo.bio
DTSTAMP:20261121T010125Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Pelareorep: Phase 2 readout est. (NCT07446322)
DESCRIPTION:Pelareorep\, phase 2\, Advanced Metastatic Colorectal Cancer.\n
 Study: FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line 
 Treatment of Metastatic RAS-Mutated\, Microsatellite-Stable Colorectal Can
 cer\nEstimated primary completion: 30 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pelareorep#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07446322
URL:https://assetmemo.bio/drug/pelareorep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
